Novavax, Inc., a biotechnology company that develops next-generation vaccines for serious infectious diseases, announced that it has closed an advance purchase agreement ( APA) with Gavi, the Vaccine Alliance (Gavi) for the supply of its recombinant protein-based COVID-19 vaccine candidate to the COVAX Facility. Under the APA, Novavax is expected to produce and distribute 350…
The Phase 3 ENSEMBLE study of the single-dose regimen of JNJ-78436735, the investigational vaccine candidate for the prevention of COVID-19 being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, continues to enroll and vaccinate study participants. ENSEMBLE is proceeding to enroll up to 60,000 participants worldwide. In addition to the single-dose regimen ENSEMBLE…
Johnson & Johnson has announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions, Inc. to support the manufacturing of its lead investigational COVID-19 vaccine candidate. The collaboration is the first in a series of prospective global collaboration agreements designed to accelerate manufacturing of Johnson & Johnson’s COVID-19 vaccine candidate,…